Characterization of the De Novo Biosynthetic Enzyme of Platelet Activating Factor, DDT-Insensitive Cholinephosphotransferase,  of Human Mesangial Cells

Tsoupras, Alexandros Basilios; Fragopoulou, Elizabeth; Nomikos, Tzortzis; Iatrou, Christos; Antonopoulou, Smaragdi; Demopoulos, Constantinos Alexandros

doi:https://doi.org/10.1155/2007/27683

Mediators of Inflammation

On this page

Abstract References Copyright Related Articles

Research Article | Open Access

Volume 2007 | Article ID 027683 | https://doi.org/10.1155/2007/27683

Characterization of the De Novo Biosynthetic Enzyme of Platelet Activating Factor, DDT-Insensitive Cholinephosphotransferase, of Human Mesangial Cells

Alexandros Basilios Tsoupras,¹Elizabeth Fragopoulou,²Tzortzis Nomikos,²Christos Iatrou,³Smaragdi Antonopoulou,²and Constantinos Alexandros Demopoulos¹

Received24 Jan 2007

Accepted08 Mar 2007

Published05 Jun 2007

Abstract

Platelet activating factor (PAF), a potent inflammatory mediator, is implicated in several proinflammatory/inflammatory diseases such as glomerulonephritis, glomerulosclerosis, atherosclerosis, cancer, allergy, and diabetes. PAF can be produced by several renal cells under appropriate stimuli and it is thought to be implicated in renal diseases. The aim of this study is the characterization of DTT-insensitive cholinephosphotransferase (PAF-CPT) of human mesangial cell (HMC), the main regulatory enzyme of PAF de novo biosynthetic pathway. Microsomal fractions of mesangial cells were isolated and enzymatic activity and kinetic parameters were determined by TLC and in vitro biological test in rabbit washed platelets. The effect of bovine serum albumin (BSA), dithiothreitol (DTT), divalent cations (Mg²⁺ and Ca²⁺), EDTA, and various chemicals on the activity of PAF-CPT of HMC was also studied. Moreover, preliminary in vitro tests have been performed with several anti-inflammatory factors such as drugs (simvastatin, IFNa, rupatadine, tinzaparin, and salicylic acid) and bioactive compounds of Mediterranean diet (resveratrol and lipids of olive oil, olive pomace, sea bass “Dicentrarchus labrax,” and gilthead sea bream “Sparus aurata”). The results indicated that the above compounds can influence PAF-CPT activity of HMC.

References

C. A. Demopoulos, R. N. Pinckard, and D. J. Hanahan, “Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators),” The Journal of Biological Chemistry, vol. 254, no. 19, pp. 9355–9358, 1979.
View at: Google Scholar
J. Benveniste, M. Tencé, P. Varenne, J. Bidault, C. Boullet, and J. Polonsky, “Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine,” Comptes Rendus des Séances de l'Académie des Sciences. Série D, Sciences Naturelles, vol. 289, no. 14, pp. 1037–1040, 1979.
View at: Google Scholar
M. L. Blank, F. Snyder, L. W. Byers, B. Brooks, and E. E. Muirhead, “Antihypertensive activity of an alkyl ether analog of phosphatidylcholine,” Biochemical and Biophysical Research Communications, vol. 90, no. 4, pp. 1194–1200, 1979.
View at: Google Scholar
S. M. Prescott, G. A. Zimmerman, D. M. Stafforini, and T. M. McIntyre, “Platelet-activating factor and related lipid mediators,” Annual Review of Biochemistry, vol. 69, pp. 419–445, 2000.
View at: Publisher Site | Google Scholar
F. Snyder, V. Fitzgerald, and M. L. Blank, “Biosynthesis of platelet-activating factor and enzyme inhibitors,” Advances in Experimental Medicine and Biology, vol. 416, pp. 5–10, 1996.
View at: Google Scholar
D. M. Stafforini, T. M. McIntyre, M. E. Carter, and S. M. Prescott, “Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor,” The Journal of Biological Chemistry, vol. 262, no. 9, pp. 4215–4222, 1987.
View at: Google Scholar
E. Francescangeli, A. Boila, and G. Goracci, “Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex,” Neurochemical Research, vol. 25, no. 5, pp. 705–713, 2000.
View at: Publisher Site | Google Scholar
F. Snyder, “CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor,” Biochimica et Biophysica Acta, vol. 1348, no. 1-2, pp. 111–116, 1997.
View at: Publisher Site | Google Scholar
K. Muguruma and J. M. Johnston, “Metabolism of platelet-activating factor in rat epididymal spermatozoa,” Biology of Reproduction, vol. 56, no. 2, pp. 529–536, 1997.
View at: Publisher Site | Google Scholar
B. O. Ibe, A. M. Portugal, and J. Usha Raj, “Metabolism of platelet activating factor by intrapulmonary vascular smooth muscle cells. Effect of oxygen on phospholipase $A_{2}$ protein expression and activities of acetyl-CoA acetyltransferase and cholinephosphotransferase,” Molecular Genetics and Metabolism, vol. 77, no. 3, pp. 237–248, 2002.
View at: Publisher Site | Google Scholar
N. Satoh, A. Harada, K. Yokoyama, K. Karasawa, K. Inoue, and M. Setaka, “Regulation of activities of cytidine $5^{'}$ -diphospho-choline:1-O-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase, an enzyme responsible for de novo synthesis of platelet-activating factor, by membrane phospholipids,” Journal of Health Science, vol. 49, no. 1, pp. 13–21, 2003.
View at: Publisher Site | Google Scholar
R. Giménez and J. Aguilar, “Cytidine ( $5^{'}$ ) diphosphocholine-induced decrease in cerebral platelet activating factor is due to inactivation of its synthesizing enzyme cholinephosphotransferase in aged rats,” Neuroscience Letters, vol. 299, no. 3, pp. 209–212, 2001.
View at: Publisher Site | Google Scholar
M. Imagawa, H. Mimata, S.-I. Takahashi, M. Nakagawa, Y. Nomura, and J. Ogata, “Modulation of platelet-activating factor synthesis by recombinant interferon- $α$ in human renal cell carcinoma,” Urologia Internationalis, vol. 57, no. 1, pp. 11–16, 1996.
View at: Google Scholar
W. Renooij and F. Snyder, “Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor and a hypotensive lipid) by cholinephosphotransferase in various rat tissues,” Biochimica et Biophysica Acta, vol. 663, no. 2, pp. 545–556, 1981.
View at: Google Scholar
X. E. Wells and C. O'Neill, “Detection and preliminary characterization of two enzymes involved in biosynthesis of platelet-activating factor in mouse oocytes, zygotes and preimplantation embryos: dithiothreitol-insensitive cytidinediphosphocholine: 1-O-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase and acetyl-coenzyme A:1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase,” Journal of Reproduction and Fertility, vol. 101, no. 2, pp. 385–391, 1994.
View at: Google Scholar
D. Schlondorff and R. Neuwirth, “Platelet-activating factor and the kidney,” The American Journal of Physiology, vol. 251, no. 1, part 2, pp. F1–F11, 1986.
View at: Google Scholar
G. Camussi, “Potential role of platelet-activating factor in renal pathophysiology,” Kidney International, vol. 29, no. 2, pp. 469–477, 1986.
View at: Google Scholar
J. M. López-Novoa, “Potential role of platelet activating factor in acute renal failure,” Kidney International, vol. 55, no. 5, pp. 1672–1682, 1999.
View at: Publisher Site | Google Scholar
A. Ortiz, M. Gomez-Chiarri, J. L. Lerma, E. Gonzalez, and J. Egido, “The role of platelet-activating factor (PAF) in experimental glomerular injury,” Lipids, vol. 26, no. 12, pp. 1310–1315, 1991.
View at: Publisher Site | Google Scholar
S. Antonopoulou, C. A. Demopoulos, C. Iatrou, G. Moustakas, and P. Zirogiannis, “Platelet-activating factor acetylhydrolase (PAF-AH) in human kidney,” International Journal of Biochemistry, vol. 26, no. 9, pp. 1157–1162, 1994.
View at: Publisher Site | Google Scholar
T. Nomikos, C. Iatrou, and C. A. Demopoulos, “Acetyl-CoA:1-O-alkyl-sn-glycero-3-phosphocholine acetyltransferase (lyso-PAF AT) activity in cortical and medullary human renal tissue,” European Journal of Biochemistry, vol. 270, no. 14, pp. 2992–3000, 2003.
View at: Publisher Site | Google Scholar
T. Nomikos, C. Iatrou, and C. A. Demopoulos, “Application of a TCA-precipitation method for the determination of 1-alkyl-sn-glycero-3-phosphate:acetyl-CoA acetyltransferase in human renal tissue,” Prostaglandins and Other Lipid Mediators, vol. 73, no. 1-2, pp. 123–140, 2004.
View at: Publisher Site | Google Scholar
E. Fragopoulou, C. Iatrou, and C. A. Demopoulos, “Characterization of acetyl-CoA: lyso-PAF acetyltransferase of human mesangial cells,” Mediators of Inflammation, vol. 2005, no. 5, pp. 263–272, 2005.
View at: Publisher Site | Google Scholar
R. Neuwirth, N. Ardaillou, and D. Schlondorff, “Extra- and intracellular metabolism of platelet-activating factor by cultured mesangial cells,” The American Journal of Physiology, vol. 256, no. 4, part 2, pp. F735–F741, 1989.
View at: Google Scholar
E. A. Lianos and A. Zanglis, “Biosynthesis and metabolism of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine in rat glomerular mesangial cells,” The Journal of Biological Chemistry, vol. 262, no. 19, pp. 8990–8993, 1987.
View at: Google Scholar
H. C. Karantonis, N. Tsantila, S. Antonopoulou et al., “In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits,” Chemistry and Physics of Lipids, vol. 130, no. 1, p. 59, 2004.
View at: Google Scholar
C. Nasopoulou, T. Nomikos, J. Rementzis, C. A. Demopoulos, and I. Zabetakis, “Biologically active lipid fractions in fish and cephalopods of the Mediterranean diet,” Chemistry and Physics of Lipids, vol. 130, no. 1, p. 63, 2004.
View at: Google Scholar
J.-D. Sraer, F. Delarue, J. Hagege et al., “Stable cell lines of T-SV40 immortalized human glomerular mesangial cells,” Kidney International, vol. 49, no. 1, pp. 267–270, 1996.
View at: Google Scholar
E. G. Bligh and W. J. Dyer, “A rapid method of total lipid extraction and purification,” Canadian Journal of Biochemistry and Physiology, vol. 37, no. 8, pp. 911–917, 1959.
View at: Google Scholar
O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951.
View at: Google Scholar
I. Izquierdo, M. Merlos, and J. García-Rafanell, “Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist—a review of pharmacological profile and clinical management of allergic rhinitis,” Drugs of Today, vol. 39, no. 6, pp. 451–468, 2003.
View at: Publisher Site | Google Scholar
C. Cortese, S. Bernardini, and C. Motti, “Atherosclerosis in light of the evidence from large statin trials,” Annali Italiani di Medicina Interna, vol. 15, no. 1, pp. 103–107, 2000.
View at: Google Scholar
N. W. C. J. van de Donk, A. C. Bloem, E. van der Spek, and H. M. Lokhorst, “New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway,” Current Pharmaceutical Design, vol. 12, no. 3, pp. 327–340, 2006.
View at: Publisher Site | Google Scholar
D. Kardamakis, “Interferons in the treatment of malignancies,” In Vivo, vol. 5, no. 6, pp. 589–597, 1991.
View at: Google Scholar
S. M. Cheer, C. J. Dunn, and R. Foster, “Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease,” Drugs, vol. 64, no. 13, pp. 1479–1502, 2004.
View at: Publisher Site | Google Scholar
K. Norrby, “Low-molecular-weight heparins and angiogenesis,” Acta Pathologica, Microbiologica et Immunologica Scandinavica, vol. 114, no. 2, pp. 79–102, 2006.
View at: Publisher Site | Google Scholar
H. Kulbertus, “Aspirin: recent advances in cardiovascular prevention,” Revue Medicale de Liege, vol. 59, no. 12, pp. 695–703, 2004.
View at: Google Scholar
C. J. Buskens, A. Ristimäki, G. J. A. Offerhaus, D. J. Richel, and J. J. B. van Lanschot, “Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma,” Scandinavian Journal of Gastroenterology, vol. 38, no. 239, pp. 87–93, 2003.
View at: Publisher Site | Google Scholar
C. Balestrieri, F. Felice, S. Piacente et al., “Relative effects of phenolic constituents from Yucca schidigera Roezl. bark on Kaposi's sarcoma cell proliferation, migration, and PAF synthesis,” Biochemical Pharmacology, vol. 71, no. 10, pp. 1479–1487, 2006.
View at: Publisher Site | Google Scholar
H. C. Karantonis, S. Antonopoulou, D. N. Perrea et al., “In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 16, no. 3, pp. 174–185, 2006.
View at: Publisher Site | Google Scholar
Y. Z. H.-Y. Hashim, C. I. R. Gill, H. McGlynn, and I. R. Rowland, “Components of olive oil and chemoprevention of colorectal cancer,” Nutrition Reviews, vol. 63, no. 11, pp. 374–386, 2005.
View at: Publisher Site | Google Scholar
C. Dentan, A. D. Tselepis, M. J. Chapman, and E. Ninio, “Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase,” Biochimica et Biophysica Acta, vol. 1299, no. 3, pp. 353–357, 1996.
View at: Publisher Site | Google Scholar
F. Bussolino, G. Pescarmona, G. Camussi, and F. Gremo, “Acetylcholine and dopamine promote the production of platelet activating factor in immature cells of chick embryonic retina,” Journal of Neurochemistry, vol. 51, no. 6, pp. 1755–1759, 1988.
View at: Publisher Site | Google Scholar
R. Heller, F. Bussolino, D. Ghigo et al., “Stimulation of platelet-activating factor synthesis in human endothelial cells by activation of the de novo pathway. Phorbol 12-myristate 13-acetate activates 1-alkyl-2-lyso-sn-glycero-3-phosphate:acetyl-CoA acetyltransferase and dithiothreitol-insensitive 1-alkyl-2-acetyl-sn-glycerol:CDP-choline cholinephosphotransferase,” The Journal of Biological Chemistry, vol. 266, no. 32, pp. 21358–21361, 1991.
View at: Google Scholar
C. A. Demopoulos, H. C. Karantonis, and S. Antonopoulou, “Platelet activating factor—a molecular link between atherosclerosis theories,” European Journal of Lipid Science and Technology, vol. 105, no. 11, pp. 705–716, 2003.
View at: Publisher Site | Google Scholar
M. Koltai, D. Hosford, P. Guinot, A. Esanu, and P. Braquet, “PAF: a review of its effects, antagonists and possible future clinical implications—part II,” Drugs, vol. 42, no. 2, pp. 174–204, 1991.
View at: Google Scholar

Copyright

Copyright © 2007 Alexandros Basilios Tsoupras et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

386

Downloads

924

Citations